exciting times, page-11

GregNZ

You are quite correct Qualitative - i.e. the similarity to DNDN is the link here.

When Quantative comes into play, although the market is the same it is a different type of targetted cancer. It has a finite market share each year.

--------------------------------------------------------
The peak price assumption from Lianeisme is incorrect.

If everything was the same when/if PRR achieve FDA Approval, the only difference would be the number of listed shares.

So the Peak Market Cap of DNDN divided by it number of listed shares gave the peak price of circa $55.

Lianeisme - You should perform the same calculations on PRR. Rather than use the SP of DNDN as your datum point.


DYOR Paul